Melatonin and breast cancer: evidences from preclinical and human studies

The breast cancer affects women with high mortality and morbidity worldwide. The risk is highest in the most developed world but also is markedly rising in the developing countries. It is well documented that melatonin has a significant anti-tumor activities demonstrated on various cancer types in a plethora of preclinical studies. In breast cancer, melatonin is capable to disrupt estrogen-dependent cell signaling, resulting in a reduction of estrogen-stimulated cells, moreover, it ’s obvious neuro-immunomodulatory effect in organism was described.
Source: Critical Reviews in Oncology Hematology - Category: Cancer & Oncology Authors: Source Type: research